Abstract
The treatment of individuals with intellectual/developmental disabilities and schizophrenia or related disorders represents a challenge for clinicians. Individuals with cognitive impairment may be especially vulnerable to the adverse effects of conventional and atypical antipsychotic drugs. We report on the successful treatment of an individual with schizoaffective disorder and intellectual disability with aripiprazole, a novel antipsychotic agent with a favorable side effect profile.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 53-56 |
| Number of pages | 4 |
| Journal | Mental Health Aspects of Developmental Disabilities |
| Volume | 7 |
| Issue number | 2 |
| State | Published - Apr 1 2004 |
Keywords
- Aripiprazole
- Atypical antipsychotics
- Diabetes mellitus
- Intellectual/developmental disability
- Mental retardation
- Psychiatric disorder
- Schizoaffective disorder
- Schizophrenia
ASJC Scopus subject areas
- Clinical Psychology
- Psychiatry and Mental health